Acute Pain Clinical Trial
Official title:
Low-dose Ketamine Versus Morphine for Severe Painful Sickle Cell Crises in Children at Mulago Hospital: A Randomised Controlled Trial
This clinical trial will inform of the role of Low dose ketamine in the acute treatment of
severe painful sickle cell crisis in children in a day-case sickle cell centre. The primary
aim is to determine whether Low dose ketamine is non inferior to morphine in the management
of acute painful sickle cell crises. The specific objectives will be to determine the
maximal change in NRS pain score following administration of ketamine and to examine the
safety profile of ketamine compared to morphine in this population.
The investigators hypothesize that low dose ketamine will result in similar effective pain
control as morphine alone and will not be associated with an increase in adverse events.
Acute pain episodes associated with sickle cell disease (SCD) are very difficult to manage
effectively. Opioid, phobia, tolerance, availability and side effects have been major
roadblocks in our ability to provide these patients with adequate pain relief.
Ketamine is cheap, widely safe, readily available drug in low-middle income setting, with
analgesic effects at sub-anesthetic doses and has a wide range of use including surgery
(opioid sparing drug), burns (change of dressing ) and cancer related pain. However
literature concerning its use in sickle cell crises is still limited in our setting.
This is a double-blinded, randomized control, study comparing low-dose ketamine (LDK) to
morphine for acute pain control in children with sickle cell crises. A sample of 240
children will be enrolled from a population of patients with Sickle Cell Anemia aged 7-18
who present to the Mulago Referral Hospital Sickle Cell Clinic with acute painful
Vaso-occlusive Crisis (VOC). To take part in the study, a patient must have a pain score of
7 and above as assessment by the treating physician in addition to the patient meeting all
other study criteria.
After enrollment, the consented patient's weight in kg will be determined at the holding
area with a standardized calibrated weighing scale (SECA - From National Medical Stores,
Uganda) before transfer to the treatment room.
Baseline clinical parameters which include pulse rate, respiratory rate, blood pressure,
temperature, oxygen saturation, level of consciousness, Numerical Rating Scale (NRS) Pain
score (with 0 being no pain and 10 being the worst pain possible) and sites of VOC pain will
be noted.
This will be followed by placement of a peripheral intravenous cannula, G22-G20 (this is
part of standard care) with subsequent fluid load of 15mls per kg of crystalloid, repeated
if required. Other non analgesic therapies will be prescribed by the primary care provider
and started concurrently.
The recruited patients will then be randomized and allocated to receive Ketamine at 1mg/kg
(study drug) or morphine at 0.1mg/kg (active control) through an intravenous infusion using
a syringe pump(Agilia, Fresenius Kabi) over 5minutes.
The vital signs and NRS and Ramsay sedation scores (RSS) will be reassessed and recorded at
5, 10 and 20 minutes after the end of the drug infusion. However, patient monitoring will be
continuous. At 20 minutes, patients with NRS of 5 and more will be given a second dose
without crossing over. Monitoring will be continued as above. If the NRS is less than 5,
they will continue to be reassessed every 20 minutes (vital signs, NRS, RSS and adverse
events) until either inpatient admission to the ward or up to 120 minutes after which they
will be cared for by the ward team..
If they require a third dose of pain medication at any time during the study, this will be
deemed as treatment failure and the treating pediatrician will be contacted to provide
further pain control.
Any Ketamine (even for morphine) side effects as listed in the risks and safety section will
monitored for among the study subjects and will treated by the study team.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04484610 -
Appropriate Opioid Quantities for Acute Pain - Pharmacist Study
|
Phase 4 | |
Recruiting |
NCT05054179 -
Pecto-Intercostal Fascial Plane Block Catheter Trial for Reduction of Sternal Pain
|
Phase 2/Phase 3 | |
Completed |
NCT04548635 -
VR for Burn Dressing Changes at Home
|
Phase 2/Phase 3 | |
Recruiting |
NCT05370404 -
Prescribing vs. Recommending Over-The-Counter (PROTECT) Analgesics for Patients With Postoperative Pain:
|
N/A | |
Completed |
NCT06054945 -
Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block
|
||
Completed |
NCT03825549 -
A Randomized Trial of Behavioral Economic Approaches to Reduce Unnecessary Opioid Prescribing
|
N/A | |
Completed |
NCT05995912 -
Efficacy and Safety of Etoricoxib-tramadol Tablet in Acute Postoperative Pain
|
Phase 2 | |
Recruiting |
NCT05589246 -
Regional Analgesia in Combination With Cryoanalgesia to Prevent Acute Pain Following Nuss Procedure
|
N/A | |
Recruiting |
NCT05572190 -
Evaluate the Safety and Pharmacokinetic Profile of ETR028 and ETR029 in Healthy Adult Subjects
|
Phase 1 | |
Terminated |
NCT04716413 -
Evaluating the Use of Sublingual Sufentanil in Patients With Suboxone Treatment
|
Phase 4 | |
Active, not recruiting |
NCT03537573 -
Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care
|
N/A | |
Not yet recruiting |
NCT06317844 -
Examination of Psychological and Physiological Pathways Linking Gratitude and Pain
|
N/A | |
Withdrawn |
NCT02957097 -
Gabapentin as a Pre-emptive Analgesic in Oral and Maxillofacial Surgical Procedures
|
Phase 4 | |
Terminated |
NCT02599870 -
Clinical Study to Evaluate Clinical Impact of PGx-Guided Treatment for Patients Undergoing Elective Spinal Surgical Procedures
|
N/A | |
Completed |
NCT02565342 -
Interscalene Brachial Plexus Block to Treat Pain After Clavicular Surgery
|
Phase 4 | |
Completed |
NCT02984098 -
40% Orally Administered Dextrose Gel is More Effective Than 25% Dextrose
|
Phase 4 | |
Completed |
NCT02380989 -
Integrative Ayurveda Healing Relieves Minor Sports Injury Pain
|
Phase 2 | |
Completed |
NCT02489630 -
Low Dose Ketamine as an Adjunct to Opiates for Acute Pain in the Emergency Department
|
Phase 4 | |
Completed |
NCT03107338 -
Preventive Treatment of Pain After Dental Implant Surgery
|
Phase 4 | |
Completed |
NCT02817477 -
Intranasal Ketamine for Acute Traumatic Pain
|
Phase 4 |